SOD1 and amyotrophic lateral sclerosis: One of the advantages of the MO approach, with respect to other therapeutic strategies, is that it allows SOD1 targeting in both neuronal and non-neuronal cells in the CNS and can thus act on both the cell-autonomous and non-cell autonomous pathogenic mechanisms of ALS.